Key result
Cardiac ECM scaffolds drive bone marrow c-kit+ progenitors to differentiate into cardiomyocyte-like cells without inducible factors.
Why the study?
Stem cell therapy for congenital heart disease is limited by low myocardial retention and an unsupportive diseased microenvironment, prompting preparation of a novel human-derived cardiac scaffold to improve stem cell function.
Does a human-derived cardiac decellularized ECM scaffold improve the adhesion, proliferation, and differentiation of bone marrow c-kit+ progenitor cells from patients with congenital heart disease?
Does a human-derived cardiac decellularized ECM scaffold improve the adhesion, proliferation, and differentiation of bone marrow c-kit+ progenitor cells from patients with congenital heart disease?
Human-derived cardiac decellularized ECM scaffolds promote the adhesion, proliferation, and spontaneous cardiac differentiation of bone marrow progenitor cells from patients with congenital heart disease in vitro.
Hypothesis-generating for ECM scaffolds in progenitor differentiation; leaves open in vivo efficacy or clinical translation in congenital heart disease.
BACKGROUND: Stem cells are used as an alternative treatment option for patients with congenital heart disease (CHD) due to their regenerative potential, but they are subject to low retention rate in the injured myocardium. Also, the diseased microenvironment in the injured myocardium may not provide healthy cues for optimal stem cell function. OBJECTIVE: In this study, we prepared a novel human-derived cardiac scaffold to improve the functional behaviors of stem cells. METHODS: Decellularized extracellular matrix (ECM) scaffolds were fabricated by removing cells of human-derived cardiac appendage tissues. Then, bone marrow c-kit+ progenitor cells from patients with congenital heart disease were seeded on the cardiac ECM scaffolds. Cell adhesion, survival, proliferation and cardiac differentiation on human cardiac decellularized ECM scaffold were evaluated in vitro. Label-free mass spectrometry was applied to analyze cardiac ECM proteins regulating cell behaviors. RESULTS: It was shown that cardiac ECM scaffolds promoted stem cell adhesion and proliferation. Importantly, bone marrow c-kit+ progenitor cells cultured on cardiac ECM scaffold for 14 days differentiated into cardiomyocyte-like cells without supplement with any inducible factors, as confirmed by the increased protein level of Gata4 and upregulated gene levels of Gata4, Nkx2.5, and cTnT. Proteomic analysis showed the proteins in cardiac ECM functioned in multiple biological activities, including regulation of cell proliferation, regulation of cell differentiation, and cardiovascular system development. CONCLUSION: The human-derived cardiac scaffold constructed in this study may help repair the damaged myocardium and hold great potential for tissue engineering application in pediatric patients with CHD.
No takes yet. Share an insight, caveat, or question.
A 2022 study studied Congenital heart disease. Human-derived cardiac decellularized ECM scaffold seeded with bone marrow c-kit+ progenitor cells was evaluated on Cell adhesion, survival, proliferation, and cardiac differentiation. Bone marrow c-kit+ progenitor cells cultured on human-derived cardiac ECM scaffolds for 14 days differentiated into cardiomyocyte-like cells without inducible factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: